AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

Description

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted thoracic tumors. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted thoracic tumors.

Conditions

Thoracic Tumors, Non-small Cell Lung Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted thoracic tumors. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted thoracic tumors.

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

Condition
Thoracic Tumors
Intervention / Treatment

-

Contacts and Locations

Bakersfield

Comprehensive Blood and Cancer Center, Bakersfield, California, United States, 93309

Duarte

City of Hope National Medical Center, Duarte, California, United States, 91010

Los Angeles

Translational Research in Oncology US Inc, Trio Central Pharmacy, Los Angeles, California, United States, 90095

Santa Monica

University of California Los Angeles, Santa Monica, California, United States, 90404

Denver

Rocky Mountain Cancer Centers, Denver, Colorado, United States, 80218

Norwich

Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States, 06360

Saint Paul

HealthPartners Institute, Saint Paul, Minnesota, United States, 55102

Kansas City

Saint Lukes Hospital of Kansas City, Kansas City, Missouri, United States, 64111

Las Vegas

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States, 89169

New York

New York University Grossman School of Medicine, New York, New York, United States, 10016

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to 100 Years

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    Amgen,

    MD, STUDY_DIRECTOR, Amgen

    Study Record Dates

    2031-10-25